News Center

Home page

Peak Report

News reports

Meet the challenge at the peak

Release time:

2020-08-14

Meeting Challenges at Peak

■ Peak Pharmaceutical Zhang Mingyin

came to Peak Pharmaceutical Company from 2010 5# November. It has been eight years in an instant. In the past eight years, for me, four words can be summed up, that is, "learning while doing", constantly enriching myself and challenging myself.

My first position in a pharmaceutical company was in the quality assurance department. I still remember the first time I reported to the central laboratory, and the director asked me, "What did I do before?" I answered, "Workshop production management." The director said, "You should follow Xu Lizhen first when you go to work tomorrow..." In this way, Xu Lizhen, a small girl with serious and meticulous work, became my first master in the peak. Under her guidance, I started with the most basic physical and chemical tests and really started from scratch. It was midsummer, 10ml control bottle sampling, we climbed up and down the warehouse busy, everyone is a big sweat. By the end of summer, I was transferred to the then Jiangnan factory for process verification. The new master Qian Shenghua was a muscular boy like Tai Sen, but his work was still as meticulous and serious. Now, my two "little masters" have reached management positions, and batch after batch of young people have been continuously enriched to key positions. From them, I feel the tolerance and trust of the peak corporate culture, and also feel 60 -year-old peak full of vitality.

Working on intellectual property was another major challenge I took on at Spike Pharmaceuticals. In 2012 , I took over the related patent application maintenance and other intellectual property work originally undertaken by the Production Technology Department. In order to do this work well, In 2013 , I obtained the first intellectual property internal auditor qualification certificate from a pharmaceutical company, laying the foundation for a series of follow-up work. In 2014 , the trademark work of the former market planning department was also merged. The pharmaceutical company set up an intellectual property department and actively introduced the enterprise intellectual property management system. The burden on my shoulders became heavier and heavier. With the support and help of leaders and colleagues from various departments, in 2015 , Jianfeng Pharmaceutical's first company intellectual property management manual was completed and issued. 2016 successfully passed the third-party certification of the enterprise's intellectual property management system and was recognized as a national intellectual property advantage enterprise; In March of the same year 9, pharmaceutical Company No. 1050800 "Peak" Trademark (Class 5 ) was recognized as a well-known trademark in China by the State Administration for Industry and Commerce. In 2017 , Jianfeng Pharmaceutical won the honorary title of National Intellectual Property Demonstration Enterprise. This is the highest-level honor for national intellectual property work. When I heard this news, don't mention how proud I was.

In fact, before I took over, Jianfeng Pharmaceutical's intellectual property work had a very solid foundation. As early as

2012 , we were rated as Jinhua patent demonstration enterprise, and 2013 became Zhejiang patent demonstration enterprise. With this foundation, the subsequent implementation and benchmarking work also came naturally. At the same time, in the process of standardization, our relevant management became more standardized and orderly, and the level of intellectual property work has made great progress. As a specific participant in this work, I not only experienced my personal growth, but also gained several "firsts": 2015 , won the title of "advanced worker" for the first time; this year, it was recommended by Jinhua Municipal Science and Technology Bureau as an advanced individual of national intellectual property work enterprises.

Looking back at the peak of eight years, I deeply realize that here, we can have the opportunity to learn, have the opportunity to create, and have the opportunity to realize the integration of personal value and enterprise. This year, the 60th anniversary of Jianfeng Group's establishment and the 20th anniversary of the establishment of the pharmaceutical company. The eight years I have experienced are only a short part of the peak process. I did not have the opportunity to participate in the earlier past, but in the next ten years, I will be with the peak. With the same, I will confidently contribute my strength to the more brilliant peak

70rd anniversary.

More information

Monitoring Report of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project

2020

07-30

Monitoring Report of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project

2020

07-31

Monitoring Report of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project

2020

07-31

Daye Jianfeng Cement Co., Ltd. Kiln End Flue Gas Desulfurization Project Completion Environmental Protection Acceptance Publicity

Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution

2020

07-31

Spike New Drug Approved for Registration

On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)

2020

07-31

Spike New Drug Approved for Registration

2020

07-31

< 1...30 31 32...61 > 跳转到页